T cells can kill tumors more effectively if a roadblock in their receptor signaling is removed, report Loeser et al. on page 879.

Figure 1Mice that lack cbl-b spontaneously reject UV-induced tumors.

Most tumors are poor targets for the immune system as they frequently lack costimulatory molecules and present antigens that are only weakly immunogenic. The few tumor-specific T cells that do get generated are tolerized and fail to see the tumor as a dangerous enemy.

Strategies to induce strong antitumor T cell responses---including cytokine treatment to coax tumors into expressing costimulatory proteins or vaccination with host dendritic cells loaded with tumor antigens---have not always worked. Loeser and colleagues decided instead to circumvent tolerogenic mechanisms within the antitumor T cells themselves.

Their target was the ubiquitin ligase cbl-b, which inhibits TCR signals by targeting downstream signaling proteins for proteasomal degradation. The group had previously shown that T cells lacking cbl-b are efficiently activated by weak antigens even in the absence of costimulation, suggesting that cbl-b functioned as an internal tolerance enforcer.

They now find that these T cells are efficient tumor killers as well. Mice lacking cbl-b were able to spontaneously reject tumors that were either injected into the animals or induced by UV exposure. Cbl-b--deficient CD8^+^ T cells destroyed tumors when transferred into wild-type animals. These cells developed into memory cells and offered long-lasting protection against tumor recurrence.

One pitfall of removing a tolerogenic T cell protein such as cbl-b is the threat of autoimmunity. The cbl-b--deficient mice do show signs of autoimmune damage. However, these side effects are not lethal, and the mice have a normal lifespan. The team now plans to test whether antitumor T cell activity in mice can be mediated by RNAi knock-down of cbl-b, as this strategy may be practical in humans. ![](jem_iti_end.jpg)
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